<DOC>
	<DOC>NCT02636608</DOC>
	<brief_summary>The study seeks to provide evidence of the effectiveness and obtain patient reported outcome (PRO) and work productivity data of the interferon-free regimen of Paritaprevir (PTV)/ritonavir (r) + Ombitasvir (OBV), ± Dasabuvir (DSV), ± Ribavirin in chronic hepatitis C virus infected participants.</brief_summary>
	<brief_title>Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary - VERITAS</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Treatmentnaïve or experienced adult male or female patients with confirmed chronic hepatitis C (CHC), genotype 1 and 4, receiving combination therapy with the interferonfree Paritaprevir (PTV)/ritonavir (r) + Ombitasvir (OBV), ± Dasabuvir (DSV), ± Ribavirin (PTV/r+OBV±DSV±RBV) according to standard of care and in line with the current local label. If RBV is coadministered with the PTV/r+OBV±DSV±RBV, it has been prescribed in line with the current local label (with special attention to contraception requirements and contraindication during pregnancy). Patients must voluntarily sign and date Subject Information Form and Informed Consent Form prior to inclusion into the study. Patient must not be participating or intending to participate in a concurrent interventional therapeutic trial. Patient has been started on PTV/r+OBV±DSV±RBV therapy no more than one (1) month prior to the study enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Observational Study</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Paritaprevir/r/Ombitasvir</keyword>
	<keyword>Dasabuvir</keyword>
	<keyword>Work Ability</keyword>
	<keyword>Quality of Life</keyword>
	<keyword>Fibrosis</keyword>
</DOC>